Paris, France – On May 17, two live cases using Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") to treat high-risk bifurcation disease was broadcasted at EuroPCR in Paris. Firehawk® is a drug-eluting stent in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®").
The two operations were conducted respectively by expert team from Fuwai Hospital of Chinese Academy of Medical Sciences and the Elisabeth Hospital in Germany. Specifically, Professor Yuejin Yang of Fuwai Hospital of Chinese Academy of Medical Sciences and his team performed an operation treating LM bifurcation disease and Dr. Christopher Naber of the Elisabeth Hospital used Firehawk® to treat LAD bifurcation disease. Both team chose to adopt the mini crush technique. In the operations of exemplary and educational importance, the two experts fully demonstrated the key points and strategies in the treatment of bifurcation disease. The two operations achieved successful outcome and the safety and efficacy of Firehawk® were highly recognized by experts in attendance.
The advancement in R&D innovation of Asian interventional devices has deeply impacted the US and European markets, and Asia may lead the industry in medical device innovations in the future. Dr. Linda Lin, First Vice President of International Business, said: "As a leading high-end medical device provider in China and Asia, MicroPort® will constantly strive for innovations, to provide better medical solutions to China and the world and benefit more patients with coronary heart diseases."